ASCLF:OTC-Ascletis Pharma Inc (USD)

COMMON STOCK | Others | OTC

Last Closing Price

USD 0.37

Change

0.00 (0.00)%

Market Cap

N/A

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Currency: N/A

Country : N/A

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CSTNL iShares VII Public Limited Com..

-1.20 (-0.29%)

 USD32.85B 19.50 N/A
DAXXF iShares Core DAX UCITS ETF (DE..

N/A

 USD22.34B N/A N/A
IISHF iShares III Plc Emerging Mkts ..

N/A

 USD9.10B N/A N/A
ZKBGF ZKB Gold ETF

+30.00 (+1.88%)

 USD8.96B N/A N/A
IHPCF iShares Public Limited Company..

-0.46 (-1.11%)

 USD8.93B 19.50 N/A
CUYTF Etn. Fr. Colruyt NV

N/A

 USD8.61B 20.58 10.33
CUYTY Etn. Fr. Colruyt NV

N/A

 USD8.17B 20.34 10.17
TOETF Tosei Corporation

N/A

 USD7.70B 151.60 -597.40
EFMSF ETFS Metal Securities Limited ..

-0.26 (-0.16%)

 USD7.39B N/A N/A
IUTSF iShares S&P/TSX 60 Index ETF

N/A

 USD6.41B N/A N/A

ETFs Containing ASCLF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Others)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.63% 30% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.63% 29% F 24% F
Trailing 12 Months  
Capital Gain 12.12% 35% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.12% 35% F 25% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.83% 9% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.83% 9% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 16.13% 56% F 84% B
Risk Adjusted Return -54.75% 6% F 10% F
Market Capitalization N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Others)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials ()

Quarterly Financials ()

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.